Bevacirel Bevacizumab Injection

About Bevacirel Bevacizumab Injection

Description:
Bevacirel (Bevacizumab) Injection is a recombinant humanized monoclonal antibody designed to inhibit vascular endothelial growth factor (VEGF), thereby preventing the formation of new blood vessels that supply tumors. It is primarily used as an anti-cancer therapy in the treatment of various malignancies, including colorectal cancer, lung cancer, renal cell carcinoma, glioblastoma, and cervical cancer.

Key Features:

• Targets VEGF to slow tumor growth

• Administered intravenously under medical supervision

• Suitable for combination therapy with chemotherapy or as monotherapy in specific cancers

• Helps improve patient survival and manage tumor progression

Indications:

• Metastatic colorectal cancer

• Non-small cell lung cancer (NSCLC)

• Renal cell carcinoma

• Glioblastoma

• Cervical cancer

Dosage & Administration:
Bevacirel Injection should be administered as per the oncologists prescription. Dose varies depending on the type of cancer, patient condition, and combination with other therapies.

Packaging:
Available in 100 mg/4 mL vials for intravenous infusion.

Storage:
Store at 28C. Protect from light. Do not freeze.

Safety Information:
Use under strict medical supervision. May cause side effects including hypertension, bleeding, proteinuria, delayed wound healing, and gastrointestinal perforation.